Evidence map›Paper›PMID 41098135›Full record

ArticleHistology and histopathology2026

Early i-IFTA: Associated factors and impact on graft outcome.

Antoine Taillandier, Tristan De Nattes, Damien Sizaret, Philippe Gatault, Christine Bonenfant, Claire Kizlik, Lucie Maigret, Marie-Christine Machet, Marion Rabant, Juliette Gueguen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Antoine TaillandierDepartment of Pathology, Tours University Hospital Center, Tours, France.
Tristan De NattesUniversity of Rouen Normandie, INSERM U1234, Rouen University Hospital Centre, Department of Nephrology, Rouen, France.
Damien SizaretDepartment of Pathology, Tours University Hospital Center, Tours, France.
Philippe GataultDepartment of Nephrology, CHU Tours, Tours, France.
Christine BonenfantPlatform of Somatic Tumor Molecular Genetics, Tours University Hospital Centre, Tours, France.
Claire KizlikPlatform of Somatic Tumor Molecular Genetics, Tours University Hospital Centre, Tours, France.
Lucie MaigretDepartment of Nephrology, CHU Tours, Tours, France.
Marie-Christine MachetDepartment of Pathology, Tours University Hospital Center, Tours, France.
Marion RabantDepartment of Pathology, Assistance Publique-Hopitaux de Paris, Hopital Necker-Enfants Maladies, University of Paris Cité, Paris, France; Necker-Enfants Malades Institute, INSERM U1151, Université of Paris Cité, Paris, France.
Juliette GueguenDepartment of Nephrology, CHU Tours, Tours, France.
Elodie Miquelestorena-StandleyINSERM U1327 ISCHEMIA Membrane Signalling and Inflammation in Reperfusion Injuries, University of Tours, Tours, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment of inflammation in scarred cortical parenchyma of kidney transplant (i-IFTA) is a criterion for chronic active T cell-mediated rejection (TCMR) and has mainly been explored in one-year protocol biopsies. We evaluated the factors, molecular profile, and one-year graft outcome associated with early i-IFTA. We included 101 kidney transplant biopsies performed within the first six months posttransplant (median=89 days), between 2009 and 2020. Interstitial inflammation Banff criteria were retrospectively re-evaluated, and diagnosis reclassification was performed according to the Banff 2022 classification. After re-evaluation, 85% of the biopsies presented no rejection, including 16% of biopsies from patients with delayed graft function, and 5% of biopsies with BK polyomavirus nephropathy. Eleven per cent (11%) of the biopsies presented histological TCMR. Delayed graft function was associated with i-IFTA severity (OR=2.78, 95% CI:1.01-7.68,

Indexed as

Graft RejectionKidney TransplantationAdultBiopsyDelayed Graft FunctionFemaleGraft SurvivalHumansKidneyMaleMiddle AgedRetrospective StudiesTreatment Outcome

Identifiers

PMID41098135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.